Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.

Detailed Description
-----------------
The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo. Secondary: Secondary objectives are to correlate neurocognitive performance effects with degree of inhibition and therefore sequestration of red blood cell AChE by huperzine A, donepezil, and galantamine, and to monitor the safety of the study drugs in healthy adult (18-39 years) males and females. In a double-blind, randomized, placebo-controlled, parallel-groups design, normal, healthy, adult male and female volunteers will be administered one of the drug/doses. They will be tested prior to and periodically for militarily relevant performance tasks for up to 8 hours post-dose and for cholinesterase levels via finger prick.

Official Title
-----------------
Evaluation of Three Potential CNS Pretreatments for Soman Exposure - Huperzine A, Donepezil, and Galantamine - on Human Performance

Conditions
-----------------
Biomarkers, Pharmacological

Intervention / Treatment
-----------------
* Drug: Huperzine A
* Drug: Donepezil
* Drug: Galantamine
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All healthy men and women 18 to 39 years of age are eligible to participate. Exclusion Criteria: Must be able to swallow whole pills. Self-reported habitual nightly sleep amounts outside the target range of 6-8 hours (i.e., less than 6 hours per night or more than 8 hours per night, on average) Cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, family history of sudden cardiac death or myocardial infarction) as determined by participant self report. Current hypertension or high blood pressure (greater than 140/90) Neurologic disorder (to include but not limited to epilepsy or another seizure disorder, amnesia for any reason, hydrocephalus, MS, narcolepsy or other sleep disorders) Kidney disease History of psychiatric disorder requiring hospitalization or psychiatric medication for any length of time Beck Depression Inventory score of 14 or above Underlying pulmonary disease requiring daily inhaler use Regular nicotine use (or addiction) (defined as more than 1 cigarette or equivalent per week) within the last 3 years Heavy alcohol use (more than 2 drinks per day; http://www.cdc.gov/alcohol/faqs.htm#10) Use of other illicit drugs (to include but not limited to benzodiazepines, amphetamines, cocaine, marijuana) Known liver disease or liver abnormalities as determined by a laboratory test Known ulcer disease or risk of ulcer disease (stomach bleeding) Self-reported history of caffeine use in excess of 400 mg (8 caffeinated sodas or 3-4 cups, each   6 oz, of coffee) per day on average Pregnancy (females) Breast-feeding (females) Prior anaphylactic reaction, angioedema, or other severe psychological reactions to any of the test compounds

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Huperzine A: 100 ug<br> | Drug: Huperzine A<br>* dosage form: tablet dose frequency: once only<br>|
| Huperzine A: 200 ug<br> | Drug: Huperzine A<br>* dosage form: tablet dose frequency: once only<br>|
| Donepezil: 2.5 mg<br> | Drug: Donepezil<br>* dosage form: tablet dosage frequency: once only<br>|
| Donepezil: 5 mg<br> | Drug: Donepezil<br>* dosage form: tablet dosage frequency: once only<br>|
| Galantamine: 4 mg<br> | Drug: Galantamine<br>* dosage form: tablet dosage frequency: once only<br>|
| Galantamine: 8 mg<br> | Drug: Galantamine<br>* dosage form: tablet dosage frequency: once only<br>|
| Placebo<br> | Other: Placebo<br>* dosage form: tablet dosage frequency: once only<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Observe military relevant neurocognitive performance in humans taking huperzine A, donepezil and galantamine compared to placebo. | The primary objective of this study is to determine whether huperzine A (a nutraceutical), donepezil (Aricept®), and galantamine (Razadyne®), impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo. | 6pm Day 1 to 7pm Day 2 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlate neurocognitive performance effects of huperzine A, donepezil and galantamine and to monitor the safety of the study drugs in healthy adults. | Secondary objectives are to correlate neurocognitive performance effects with degree of sequestration of red blood cell AChE by huperzine A, donepezil, and galantamine, and to monitor the safety of the study drugs in healthy adults. | 6pm Day 1 to 7pm Day 2 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Central nervous system, Cholinesterase, Neurocognitive performance testing